NCT00995540View on ClinicalTrials.gov

Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults

PHASE2TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

INGAP Peptide

100 mg INGAP Peptide tid subcutaneous injection for 12 weeks

DRUG

INGAP Peptide

200 mg INGAP Peptide tid subcutaneous injection for 12 weeks

DRUG

Placebo

Placebo tid subcutaneous injection for 12 weeks

Trial Locations (2)

55905

Mayo Clinic, Rochester

H3G 1A4

McGill University - Montreal General Hospital, Montreal

Sponsors
All Listed Sponsors
lead

Exsulin Corporation

INDUSTRY